Sign in

    Jo Yi Chudy • Stifel

    Jo Yi Chudy is an analyst at Stifel, Nicolaus & Company, leveraging her expertise in financial markets to provide in-depth equities analysis. She covers a diverse range of companies across market sectors, drawing on a strong analytical background to inform investment recommendations. Chudy began her professional finance career in recent years at Stifel, where she has developed a solid reputation for research diligence and client service. She holds active FINRA registrations, reflecting her completion of key securities licensing requirements necessary for her role as an equity research analyst.

    Jo Yi Chudy's questions to Vistagen Therapeutics Inc (VTGN) leadership

    Jo Yi Chudy's questions to Vistagen Therapeutics Inc (VTGN) leadership • Q3 2025

    Question

    Jo Yi Chudy of Stifel questioned the rationale for the ongoing repeat-dose study of fasedienol, the expected outcomes, and any potential regulatory risks if a two-dose regimen appears more effective than a single dose.

    Answer

    COO Joshua Prince clarified that the repeat-dose study was requested by the FDA to evaluate the safety and potential efficacy of a second dose. He and CEO Shawn Singh conveyed that they do not anticipate regulatory issues if the single-dose PALISADE trials are successful, as the repeat-dose study is smaller and primarily intended to inform the product's label regarding real-world use. Prince noted that while some patients might benefit, receptor saturation could limit the additional effect of a second dose.

    Ask Fintool Equity Research AI